Cost-Effectiveness Analysis of Triple Oral Antidiabetic Drug Combination in Patients with Type 2 Diabetes Mellitus
An Outpatient Study in Indonesia
DOI:
https://doi.org/10.15605/jafes.041.02.6321Keywords:
type 2 diabetes mellitus, metformin, dipeptidyl-peptidase IV inhibitors, cost-effectiveness analysis, drug combinations, IndonesiaAbstract
Background. Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. Initial therapy for type 2 diabetes typically starts with metformin monotherapy, but because of its progressive nature, combination therapy is often required to achieve glycemic targets. However, research on combination therapy with three oral antidiabetic drugs is currently limited.
Objective. This study assessed direct medical costs and the cost-effectiveness of a combination of triple oral antidiabetics with first-line metformin combined with glimepiride, pioglitazone, and DPP-4 inhibitors (sitagliptin/vildagliptin), among type 2 DM patients treated in the outpatient clinic of dr. Ramelan Central Naval Hospital, Surabaya, Indonesia.
Methodology. A retrospective cross-sectional analysis was conducted from the hospital perspective using medical records and cost data from January to December 2024. Eligible patients had type 2 DM, received a combination of triple oral antidiabetics with metformin as first-line treatment combined with glimepiride, pioglitazone, and DPP-4 inhibitors (sitagliptin/vildagliptin), attended monthly follow-ups, had at least two HbA1c measurements, and had complete clinical and cost data. Direct medical costs included doctor services, drug acquisition costs, and laboratory monitoring costs.
Results. A total of 79 patients were included, 60.8% male, with an average (SD) age of 54.9 (9.26) years, and 69.6% with comorbidities. Compared with the combination of metformin + glimepiride + pioglitazone, the combination of metformin + sitagliptin/vildagliptin + glimepiride and metformin + sitagliptin/vildagliptin + pioglitazone was more cost-effective, with ICER values of IDR -162,119.77; IDR 845,655.5, respectively. Both ICER values were below the willingness-to-pay (WTP) threshold. One-way sensitivity analysis showed that the model results were relatively robust to parameter variations of ±20%. In the combination of metformin + sitagliptin/vildagliptin +glimepiride vs metformin + glimepiride + pioglitazone, laboratory monitoring costs had the greatest influence on the ICER value. Meanwhile, the combination comparison metformin + sitagliptin/vildagliptin + pioglitazone vs metformin + glimepiride + pioglitazone was most sensitive to changes in effectiveness (ΔHbA1c).
Conclusion. Metformin + sitagliptin/vildagliptin + glimepiride and metformin + sitagliptin/vildagliptin + pioglitazone are both more cost-effective compared to metformin+ glimepiride+pioglitazone in this setting.
Downloads
References
1. Ekhlasi M, Taheri S, Yousefi N. Cost-effectiveness of dulaglutide versus liraglutide for management of type 2 diabetes mellitus in Iran. Value in Health Reg Issues. 2022;32:54–61. https://pubmed.ncbi.nlm.nih.gov/36087364 https://doi.org/10.1016/j.vhri.2022.07.005
2. Pawaskar M, Bilir SP, Kowal S, Li Q, Weiss T, Davies G. Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes. Am J Manag Care. 2021;27(8):e269–77. https://pubmed.ncbi.nlm.nih.gov/34460181 https://doi.org/10.37765/ajmc.2021.88728
3. International Diabetes Federation. IDF Diabetes Atlas. https://diabetesatlas.org/
4. American Diabetes Association Professional Practice Committee. Standards of care in diabetes—2025. Diabetes Care. 2025;48(suppl 1):S1-S359.
5. Patty YFPP, Nita Y, Libriansyah. IAI special edition: Cost of illness analysis of diabetes mellitus with complications in one hospital in Surabaya. Pharm Educ. 2022;22(2):254–8. https://doi.org/10.46542/pe.2022.222.254258
6. Perkumpulan Endokrinologi Indonesia. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. PB Perkeni; 2021.
7. Yusmaniar, Kurniawan AH, Surahman, Fauzan MN. Treatment pattern and cost-effectiveness analysis of oral hypoglycemics for type 2 diabetes mellitus outpatients at regional general hospital, Indonesia. Malays J Public Health Med. 2022;22(2):27–34. https://doi.org/10.37268/mjphm/vol.22/no.2/art.1615
8. Hanifiyah IA, Nita Y, Libriansyah, Ridwan A. A systematic review: Cost-effectiveness of SGLT2 inhibitors versus DPP-4 Inhibitors as Add-on to Metformin. Jurnal Farmasi dan Ilmu Kefarmasian Indonesia. 2025;12(2):255–62. https://doi.org/10.20473/jfiki.v12i22025.256-263
9. Hanifa RS, Rokhman MR, Fritz M, et al. Cost-effectiveness of community-based type 2 diabetes prevention and control in Indonesia: a health economics modelling study. bmjph. 2025;3(2):e002161. https://pubmed.ncbi.nlm.nih.gov/41069974 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506045 https://doi.org/10.1136/bmjph-2024-002161
10. Trujillo JM, Haines ST. Endocrinologic Disorders. In: DiPiro’s Pharmacotherapy: A pathophysiologic approach, 12th ed. New York: McGraw Hill Medical; 2023.
11. Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011;183(16):E1213–20. https://pubmed.ncbi.nlm.nih.gov/21969406 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216433 https://doi.org/10.1503/cmaj.110178
12. Wieczorek A, Rys P, Skrzekowska-Baran I, Malecki M. The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus. Rev Diabet Stud. 2008;5(3):128–35. https://pubmed.ncbi.nlm.nih.gov/19099084 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613271 https://doi.org/10.1900/RDS.2008.5.128
13. Badan Penyelenggara Jaminan Sosial Kesehatan. Peraturan Badan Penyelenggara Jaminan Sosial Kesehatan Nomor 3 Tahun 2024 tentang Pelayanan Skrining Riwayat Kesehatan, Pelayanan Penapisan atau Skrining Kesehatan Tertentu, dan Peningkatan Kesehatan bagi Peserta Penderita Penyakit Kronis dalam Program Jaminan Kesehatan. Published November 11, 2024
14. Filipova EP, Uzunova KH, Vekov TY. Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. Diabetol Metab Syndr. 2015;7(1):63. https://pubmed.ncbi.nlm.nih.gov/26288659 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539691 https://doi.org/10.1186/s13098-015-0059-7
15. Del Prato S, Chilton R. Practical strategies for improving outcomes in T2DM The potential role of pioglitazone and DPP-4 inhibitors. Diabetes Obesity Metabolism. 2018;20(4):786–99. https://pubmed.ncbi.nlm.nih.gov/29171700 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887932 https://doi.org/10.1111/dom.13169
16. Hirao K, Maeda H, Shirabe SI, et al. Combination therapy with a dipeptidyl peptidase-4 inhibitor, sulfonylurea, and metformin markedly improves HbA1c levels in Japanese patients with type 2 diabetes mellitus. Jpn Clin Med. 2012 ;3:1-7. https://pubmed.ncbi.nlm.nih.gov/23946679 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738556 https://doi.org/10.4137/JCM.S8571
17. Rascati KL. Essentials of pharmacoeconomics, 2nd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
18. Chakravarty A, Rastogi M, Dhankhar P, Bell KF. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics. 2018;21(5):497–509. https://pubmed.ncbi.nlm.nih.gov/29376760 https://doi.org/10.1080/13696998.2018.1434182
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Izzatu Al Hanifiyah, Yunita Nita, Libriansyah, Achmad Ridwan, Gusti Noorrizka Veronika Achmad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
